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Purpose: To report the clinical and immunological characterization of 
paraneoplastic retinopathy and to investigate the association between spectral 
domain-optical coherence tomography (SD-OCT) findings and the target of 
autoantibodies in paraneoplastic retinopathy (PR).  
Design: Observational case series. 
Methods: We retrospectively enrolled 8 patients (age, 57–85 years; 4 men and 
4 women) suspected to have PR. All patients underwent comprehensive 
ophthalmic examinations, including best-corrected visual acuity (BCVA) 
measurement, slit-lamp examinations, kinetic visual field testing with Goldmann 
perimetry (GP), electroretinography (ERG), fundus photography, fluorescein 
angiography (FA), fundus autofluorescence (FAF), SD-OCT, and experimental 
serum examinations (Western blot analysis and immunohistochemistry [IHC]).  
Results: Three patients had previous history of malignant tumors, and 4 were 
newly diagnosed with neoplastic tumors (small cell lung carcinoma, thymoma, 
pancreatic neuroendocrine neoplasm, and colon cancer). Another de novo 
malignancy (small cell lung carcinoma) was detected in 1 patient with a previous 
history of malignancy (bladder cancer and liposarcoma). BCVA in these patients 
ranged from hand motion to 1.5. The GP revealed island, ring-shaped, 
concentric, or central scotoma. All the patients showed non-recordable or 
reduced amplitude ERG. Fluorescein leakage was detected in 5 patients. Hyper- 
and/or hypo- autofluorescence on FAF was detected in 6 cases. The serum 
examinations identified anti-retinal antibodies in all of the patients. Patients 
whose serum contained anti-photoreceptor or anti-RPE antibody as evidenced 
with IHC showed damages of outer retina in OCT.  
Conclusions: In this case series, PR was associated with a variety of 
neoplasms and autoantibodies. SD-OCT can be used to characterize 






Autoimmune retinopathy (AIR) is a progressive retinal degeneration caused by 
autoimmune processes. These processes are considered to be mediated by 
autoantibodies directed to retinal proteins. AIR cases with underlying malignant 
or benign tumors are termed paraneoplastic retinopathies (PRs). This 
classification includes cancer-associated retinopathy (CAR), 
melanoma-associated retinopathy (MAR),1 and lymphoma-associated 
retinopathy (LAR).2 One mechanism for PR development is hypothesized as the 
production of autoantibodies against common proteins expressed in both the 
neoplasm and the retina.3 4 
 PR was first described in 1976 by Sawyer et al.5 Subsequent case 
reports classified characteristic clinical features including a sudden and 
progressive loss of vision associated with photopsia, ring scotoma or concentric 
visual field defects, attenuated retinal arterioles, and abnormal 
electroretinograms (ERG).1 The presence of circulating serum autoantibodies 
specific to retinal antigens is necessary for a diagnosis of PR; however, this 
laboratory test is not available in most ophthalmological settings.6 Western blot 
can be used to detect anti-retinal antibodies.7 However, the lack of 
standardization across studies makes it difficult to compare the results obtained 
by various authors.8-10  
 Recent progress in imaging technology has allowed us to detect detailed 
retinal changes and provided insight into the pathological mechanisms 
underlying retinal diseases. Optical coherence tomography (OCT), which allows 
for the noninvasive visualization of normal retina as well as of pathologic 
conditions, is now widely accepted as a standard tool in clinical practice.11 The 
currently available spectral domain-OCT (SD-OCT) machines achieve resolution 
up to 5 µm; indeed, recent SD-OCT devices allow for “layer by layer” evaluation 
of the retina.12, 13 Previous reports showed that various imaging modalities can 
be used to strengthen a diagnosis of CAR or PR.14, 15 However, there is limited 
information about the SD-OCT findings associated with PRs. One of the 
purposes of this study is to find any clinical characteristic features including 
SD-OCT findings seen in patients with PR. We also investigated the association 
with clinical characteristics and serum testing (e.g., Western blot analysis and 
immunohistochemistry [IHC]) to confirm the diagnosis and to understand the 





Subjects and clinical examinations 
The study comprised of 8 patients (4 men and 4 women) who were seen at 
Kyoto University Hospital (Kyoto, Japan) from June 2008 to August 2011 and 
who were suspected to have PR. The study was conducted in accordance with 
the tenets of the Declaration of Helsinki. The study design was approved by the 
Ethics committee of Kyoto University. Two of the 8 patients were presented in a 
prior case report without describing Western blot data and OCT findings.16 
 PR was suspected when a patient showed rapidly progressing vision 
loss and/or a visual acuity defect, which cannot be explained by fundus 
examination findings or the pathophysiology of other retinal or optic nerve 
diseases. The attenuation of retinal arterioles or the presence of photophobia 
was considered to support a diagnosis of PR. In such cases, we performed 
Goldmann perimetry (GP), ERG, fluorescein angiography (FA), fundus 
autofluorescence imaging (FAF), and SD-OCT. Systemic screening was 
accomplished using computed tomography (CT). Additional examinations with 
endoscopy or bronchoscopy were performed as needed. Informed consent was 
obtained from the participants after the objectives and the nature of the 
procedures had been explained fully; blood samples were collected thereafter. 
We diagnosed patients as having PR when they showed: (1) reduced amplitude 
of ERG; (2) presence of anti-retinal autoantibodies; (3) previous or newly 
detected neoplasm; (4) acute or subacute disease progression.  
 Retinal section images were acquired using a Spectralis HRA+OCT® 
(Heidelberg Engineering, Heidelberg, Germany). Built-in Automatic Real Time 
(ART) software was used to average images in order to improve the signal to 
noise ratio. We obtained 9-mm cross sections setting the ART function to 100 
frames per scan. We also acquired 9-mm radial sections centered on the fovea, 
for which 20 images were averaged. FAF and FA images were obtained using 
confocal angiography (HRA2; Heidelberg Engineering). Full-field ERGs were 
recorded using LS-C (Mayo Co, Nagoya, Japan) and Neuropack MEB-2204 
(Nihon Kohden, Tokyo, Japan) software according to the ISCEV standard 
protocol recommended in 2008.17  
 
Western Blot Analysis  
Serum was obtained from each patient and analyzed by Western blot as 
previously reported.18 Briefly, retina, brain, kidney, liver, and spleen tissue 
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samples from C57BL/6 mice were homogenized. Extracted proteins were used 
to detect organ-specific antibodies. Proteins from each organ were separated by 
8% or 10% SDS-PAGE electrophoresis and transferred to polyvinylidene 
difluoride (PVDF) membranes. The membrane was probed with the patient’s 
serum, then rinsed and incubated with alkaline phosphatase-conjugated goat 
anti-human IgG (Jackson Immuno Research, West Grove, PA). The associated 
signal was detected with a BCIP (5-bromo-4-chloro-3'-indolylphosphatase 
p-toluidine salt) /NBT (nitro-blue tetrazolium chloride) (BCIP/NBT) detection 
system. When bands were observed in retina and/or brain lanes but not in the 
other lanes, the serum was judged as having anti-retina specific antibodies. In 
addition, the presence of anti-recoverin antibody was investigated using a 
commercial product provided by Athena Diagnostics (Worcester, MA). 
 
Immunohistochemistry (IHC) 
C57BL/6 mouse eyes were fixed by immersion at 4°C for 12 h in a freshly 
prepared solution of 0.5% zinc chloride, 17.16 mM zinc trifluoroacetate, and 
0.05% calcium acetate in 0.1 M Tris-HCl pH 6.5, then embedded in paraffin. 
Four-µm–thick sections were prepared, deparaffinized, and blocked with 4% 
normal goat serum, 0.1% Triton X-100, and 0.05% NP-40 in PBS for 1 h at room 
temperature. The slides were then incubated with a 1:50 dilution of the patient’s 
serum overnight at 4°C. Next, the specimens were rinsed in PBS and incubated 
with the Alexa Fluor 488-conjugated anti-human IgG antibody (Invitrogen, 
Carlsbad, CA). In some cases, the retinal slices were co-incubated with 
rhodamine-conjugated peanut agglutinin (Sigma-Aldrich, St. Louis, MO), rabbit 
polyclonal antibodies against blue opsin (Chemicon, Temecula, CA) or S-100 
protein (Dako, Glostrup, Denmark). These antibodies were used to label the 
outer segments of cone cells, the outer segments of s-cone cells and Müller cells, 
respectively. In these cases, Alexa Fluor 594-conjugated anti-rabbit IgG was 
used as a secondary antibody. The slides were finally mounted in a mounting 
medium containing diamidino-2-phenylindole (DAPI) (Vector Laboratories, 
Burlingame, CA). The contribution of secondary antibodies to the observed 
immune reaction was verified by staining without the primary antibody. The 
sections were examined using a confocal scanning microscope (LSM 5 Exciter, 





Genomic DNAs were prepared from peripheral blood using a DNA extraction kit 
(QuickGene-610L; Fujifilm, Minato, Tokyo, Japan) according to the 
manufacturer’s protocol, and the A260/A280 optical density was evaluated. The 
DNA from each patient except that of case 3 was submitted to genetic analysis 
to exclude the presence of genes linked to retinal degeneration: CERKL, 
CNGA1, CNGB1, MERTK, PED6A, PED6B, PNR, RDH12, RGR, RLBP1, SAG, 
TULP1, CRB, RPE65, USH2A, USH3A, LRAT, PROML1, and PBP3. The tests 




The clinical findings are summarized in Table. Initial BCVA ranged from hand 
motion to 1.5. All patients complained of reduced visual acuity or visual field 
defects. GP showed island, ring-shaped, concentric, or central scotoma. 
The ERG results are shown in Figure 1. ERG revealed abnormalities in 
all cases, but the degree of impairment ranged from non-recordable to slight 
changes in the cone response in one eye.  
 Vasculitis as confirmed by fluorescein leakage from the vasculature was 
observed in 5 cases (cases 2, 3, 4, 5, and 7). Two patients (cases 3 and 4) also 
had vitreous opacities. FA revealed a petaloid leakage in case 4. 
 Three patients had previous history of malignant tumors (Bladder cancer, 
liposarcoma, thymoma, renal cancer, lymphoma, and renal cancer), and 4 were 
newly diagnosed with neoplastic tumors (small cell lung carcinoma, thymoma, 
pancreatic neuroendocrine neoplasm, and colon cancer). Another de novo 
malignancy (small cell lung carcinoma) was detected in 1 patient with a previous 
history of malignancy (bladder cancer and liposarcoma). 
 
Fundus autofluorescence findings 
In most cases, abnormality of FAF was detected. Abnormal hyper- and/or hypo- 
autofluorescence was noted at presentation except for case 5 and 8 (Figure 2). 
Although cases 5 and 8 displayed no detectable abnormality at initial 
examination, case 8 developed abnormal hyper- and hypo- autofluorescent 






OCT images revealed evidence of retinal degeneration in all cases, especially in 
outer retina (Figure 2, right). The detected changes include the obscuration, the 
interruption, or the disappearance of the inner and outer segments junction of 
the photoreceptors (IS/OS). External limiting membrane (ELM) was also affected 
in case 1, 2, 3, 4, 5, 7, and 8. Thinning of foveal or parafoveal outer nuclear layer 
was noted in case 2, 3, 4, 6, 7, and 8. Case 4 showed cystoid macular edema.  
 
Western blot 
The results of Western blot are shown in Figure 3 and Table. Western blot 
analysis detected anti-retinal antibodies in all sera samples. Several bands 
specific to retinal proteins were observed. Anti-recoverin antibody was present in 
case 2. The molecular weights and the number of bands detected varied among 
patients.  
 
Comparison between Immunohistochemistry and SD-OCT 
High-magnification IHC and OCT images are shown in Figure 4. Abnormalities of 
outer retina were more easily confirmed in magnified SD-OCT images (Figure 4, 
upper panels). Patients’ serum reacted to retinal tissue as shown in the lower 
panels of Figure 4.  
In cases 2, 3, 4, and 5, SD-OCT showed disruption of outer retinal 
structures (Figure 4-2, 3, 4, and 5). IHC staining was detected in inner or outer 
segment in these cases (Figure 4-B, C, D, and E). In cases 7 and 8, IHC staining 
was detected in RPE layer (Figure 4-G, H) and OCT showed the obscuration of 
IS/OS line (Figure 4-7, 8). Case 1, which showed strong staining in the inner 
retinal layers on IHC had relatively preserved outer retina on SD-OCT image 
(Figure 4-1, A). In case 6, IHC staining was most prominent in the ganglion cell 
layer (Figure 4-F). SD-OCT image showed the thinning of outer nuclear layer, 
interruption of IS/OS (Figure 4-6). In addition, thinning of retinal nerve fiber layer 
was noted in this case (Figure 2-R).  
 
Genetic analysis 
To rule out genetic retinal degenerations, mutation screening was carried out by 
using microarray of Asper Opthalmics. Candidate gene mutations included 
CERKL, CNGA1, CNGB1, MERTK, PED6A, PED6B, PNR, RDH12, RGR, 
RLBP1, SAG, TULP1, CRB, RPE65, USH2A, USH3A, LRAT, PROML1, and 
PBP3. No mutations were detected on these 7 patients by the analysis. Mutation 
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screening was not perfomed in case 3 because informed consent about genetic 
analysis was not obtained.     
 
Discussion 
In the present study, we reported 8 patients with PR induced by various tumors. 
The underlying neoplasms that induced PR were bladder cancer, liposarcoma, 
thymoma, lymphoma, and renal cancer. In 5 patients, diagnoses of SCLC, 
thymoma, pancreatic neuroendocrine neoplasm, and colon cancer were made 
after patients presented with retinopathy. Although SCLC is the most common 
cause of PR,1, 4, 5, 6, 16,19-21 other systemic neoplasms including bladder cancer, 
thymoma, liposarcoma, and renal cancer have also been associated with PR.4, 22 
Neuroendocrine carcinoma of the fallopian tube has also been reported as a 
cause of PR.23 To our best knowledge, pancreatic neuroendocrine neoplasm has 
not been reported as a cause of PR. 
In PR, autoantibodies against retinal antigens are considered to cause 
retinal dysfunction and retinal cell death. Anti-recoverin antibody, which 
recognizes a 23 kDa retinal protein found in rod and cone photoreceptors as well 
as tumor cells, is the most studied autoantibody.20-22, 24-27 Anti-recoverin 
autoantibodies bind to photoreceptor cells and triggers apoptosis.21, 28, 29 In the 
present study, anti-recoverin antibody was detected in only one patient (Case 2) 
and the other patients showed unidentified antibodies. The protein targets of 
autoantibodies reported to cause PR to date include retinal alpha-enolase (46 
kDa);30-32 arrestin (48 kDa);33, 34 Tubby-like protein 1 (TULP1) (78 kDa);35 heat 
shock cognate protein (hsc) 70 (65 kDa);36, 37 transducin beta (35 kDa);38 
anti-carbonic anhydrase II (30 kDa); photoreceptor cell-specific nuclear 
receptor(46.5 kDa);39 interphotoreceptor retinoid binding protein (145 kDa);40 
TRPM1 (～180 kDa or ～200 kDa)41, 42. A number of retinal antigen that were 
not identified have been described by western blot analysis.7, 8, 43 In the present 
study, anti-recoverin antibody was detected in only one patients and western 
blot detected a various bands. We were not able to determine antigens for 
various molecular weight proteins. However, for example, in case1, a band of 
molecular weight 36 kDa was detected in Western blot, which was close to 
molecular weights of 35 kDa reported by Peek et al as antigen against Müller 
cells44 and in fact, Müller cells were stained in this case. In case 5, Western blot 
detected a band of molecular weight 46 kDa. Although the protein was not 
identified, anti-alpha-enolase antibodies (46 kDa) were reported as a cause of 
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cone dysfunction.32 Central visual field defect and almost non-recordable cone 
ERG in this patient is consistent with the report. Although it is not clear that all 
the detected bands have pathologic significance, the existence of these various 
autoantibodies, suggests that the pathology, symptoms, and clinical signs of PR 
are multi-faceted. 
 In the present study, SD-OCT images were compared to the results of 
IHC or Western blot. The patients with presumed anti-photoreceptor antibodies 
(cases 2, 3, 4, and 5) and anti-RPE antibodies (cases 7 and 8) exhibited severe 
damage to the outer retina and poor visual acuity. However, the patients without 
presumed anti-photoreceptor or anti-RPE antibodies (cases 1 and 6) exhibited 
relatively preserved IS/OS lines and had good visual acuity. This result is 
consistent with the report by Kondo et al. In their report, a patient with 
anti-TRPM1 antibody, which is expressed in ON bipolar cells, presented signals 
of INL and OPL but not photoreceptor degeneration in IHC and almost normal 
retinal structure in OCT images.42 The severe degeneration of photoreceptors 
depicted with SD-OCT might be associated with the presence of 
anti-photoreceptor or anti-RPE antibodies. Although this was an observational 
study and further investigations are needed, SD-OCT may facilitate the 
management of PR cases.15 
 FAF was also useful to detect the abnormality in patients with PR, as 
shown in previous reports.15, 45 In fact, abnormal FAF was noted in 7 out of 8 
patients. Variety of the appearance including perivascular 
hyperautofluorescence and mottled hypoautofluorescence or ring-shaped 
hyperautofluorescence was consistent with the previous report.15 In the present 
study, there was one patient who showed normal FAF. A patient with normal FAF 
was also noted in the previous report and the authors suggested several 
explanations, 1: the patient was identified very early in the disease process. 2: 
the autoantibodies alter normal retinal function but did not cause cell loss. 3: 
vision loss was due to inner retinal dysfunction rather than photoreceptor 
disruption or loss.15 In the present study, the first explanation above was not 
likely because abnormality of FAF was not observed even after 12 months. The 
second and third explanation was not applicable either, since OCT and ERG 
showed outer retinal abnormality. Further studies are required to understand the 
relationship between retinal dysfunction, pathologic process, and FAF finding in 
patients with PR. 
It was reported that retinopathy sometimes precedes the detection of 
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malignancy.4 In fact, neoplasms were detected after the presentation of 
retinopathy in 5 out of 8 patients in the present series. Thus, it is important to 
diagnose PR in a timely fashion. PR presented in our study shared the 
characteristics with previously reported cases: rapid, progressive, painless 
vision loss associated with photosensitivity that continued over a period ranging 
from weeks to months. In addition, patients with PR sometimes show 
asymmetric involvement in the right and left eyes, as shown in case 6. This 
characteristic is atypical among patients with inherited retinal degeneration. 
Although it is still a challenge to diagnose PR in many cases because of the 
variety of clinical appearances and the technical difficulty of detecting 
autoantibodies in serum,8 clinicians should be careful when faced with a case 
with rapid, atypical or asymmetric retinal degeneration.  
 In addition to the difficulty of achieving an accurate PR diagnosis and 
despite the common use of steroids to treat PR, no definitive therapeutic 
protocol has been established.7 The prognosis is not good in many cases. In fact, 
5 of 8 patients eventually display visual acuity worse than 0.1 in both eyes. 
Further investigations are warranted to establish effective treatment for this 
disease. 
Some cases with CAR were reported to show specific ERG patterns. For 
example, negative ERG results were reported in patients with MAR or with 
anti-TRPM1 (～180kDa or ～200kDa) antibody.42 In the current study, scotopic 
and photopic ERG results were equally affected in 7 cases, none of which 
exhibited a negative pattern. Adamus et al. reported that anti-enolase (46 kDa) 
antibody predominantly affected the photopic response, while anti-transducin 
(40 kDa) antibody predominantly affected the scotopic response, and 
anti-recoverin antibody reduced both responses.1 Anti-46 kDa protein antibody 
was seen in cases 5 and 7, scotopic and photopic ERG results were equally 
affected. Although case 6 exhibited a reduced cone response in the right eye, he 
did not have anti-46 kDa protein antibody. We did not find any specific 
correlation between laboratory data and ERG findings in this series of patients. 
There are several limitations in this study. The first is its retrospective 
design and the small number of patients. The second limitation is that we were 
not able to identify the anti-retinal antibody. Considering that Shimazaki et al. 
reported the presence of anti-retinal antibodies in normal sera,46 all the 
antibodies detected in the present report might not always be the cause of the 
patient’s PR. With regard to the anti-retinal antibody, there is another limitation; 
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Western blot and IHC were performed using mice retina. Although the human 
retina would be most suitable for the detection of autoantibodies, human sample 
was not available. Considering that a previous study indicates that the retina 
from other species can be a substitute as long as there is an appropriate 
control,8 we assume that the effect of using mice retina instead of human retina 
should be minimal. In fact, most previous studies used bovine, pig, monkey, rat, 
and mouse as well as human retina.7, 18, 20, 31, 35, 36, 40, 44, 47, 48 The third limitation is 
the clinical diagnosis of PR. Although we screened major genetic mutations and 
the presentation is not typical, we could not completely rule out genetic retinal 
degenerations in our cases.  
Finally, we reported the result of clinical findings and experimental serum 
examinations in 8 patients with PR. Although there was a variety in morphologic 
changes depicted with SD-OCT as well as in targets of autoantibodies, SD-OCT 
and IHC findings showed some correlation. SD-OCT might be a potential tool for 
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Electroretinogram of a patient with paraneoplastic retinopathy. Most patients 
showed reduced responses on both photopic and scotopic ERGs. Only case 6 
showed normal scotopic responses. The numbers are matched to those 





Color fundus images (left row), fundus autofluorescence images (middle row) 
and spectral domain-optical coherence tomography (SD-OCT) images (right 
row) of 8 cases with paraneoplastic retinopathy. 
The numbers are matched to those in the Table. All images are from the right 
eye. SD-OCT images are horizontal scan of case 2, 5, 6, and 8 and vertical scan 
of case 1, 3, 4, and 7. Autofluorescent images revealed the abnormal hyper- 
and/or hypo- autofluorescent lesions with an inter-individual variability in six 
cases. The SD-OCT images revealed retinal degeneration in all eyes.  
 
Figure 3. 
Western blot of mouse retina stained with patients’ sera as the first antibodies. 
10% SDS-PAGE is shown and the numbers are matched to those in the Table. 
Whether the bands were specific to retina or not was judged using lysates of 
other organs (graphic data not shown). The arrowhead shows retina-specific 
antibodies. The bands over 150 kDa were detected by 8% SDS-PAGE and they 
were not shown in this image.   
 
Figure 4. 
Comparison of spectral domain optical coherene tomography (SD-OCT) and 
immunohistochemistry (IHC) images of patients with paraneoplastic retinopathy. 
The numbers are matched to those in the Table. The top shows OCT images at 
higher magnification (1-8). Panels A-H are IHC images that show mouse retina 
stained with patient serum as the first antibody (green). Cell nuclei are visualized 
with DAPI (blue). S-100 protein was also used to label the Müller cell in case 
1(red). The control is presented on the bottom left panel. SD-OCT revealed 
abnormalities in external limiting membrane (ELM) or inner segment/outer 
segment junction (IS/OS) in all cases. IHC images showed that patients’ sera 
contained antibodies that bind to various retinal proteins. White arrows indicate 
the site where anti-retinal antibodies in patient’s sera reacted to retinal tissue. 
The scale bar represents 20 µm. GCL, ganglion cell layer; IPL, inner plexiform 
layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear 
layer; IS, inner segment of photoreceptor; OS, outer segment of photoreceptor.  
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 Table. Clinical Characteristics and Treatment of Neoplasm and Pareneoplastic Retinopathy and Result of Western Blot Analysis of 8 Cases.
Serum Examination

















Died within 3 months
Case2
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Died within 1 year
Case4
 81F
Decrease of VA 0.09
40 cm
/HM
B) Central scotoma +
Subnormal in cone
 NR in remainder
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GCL, ,INL and OPL
VA stable
 for 2 years
Case7
61M
Decrease of VA 0.3 0.2
























B) Central and ring
scotoma
- Subnormal
 no specific finding Colon cancer Surgery Non-treatment
25,30,90,174/
RPE
VA declined to hand
motion in both eyes
in 3 years
Course
BCVA, best corrected visual acuity; FA, fluorescein angiography; WB, wester blot; IHC, immunohistochemistory; VF, visual field; SCLC, small cell lung cancer; IVIg, intravenous immunogloblin;OS, outer segment ; VA, visual acuity;  HM, hand motion; NR, non-
recordable; GCL, ganglion cell layer; IS, innner segment; OPL, outer plexiform layer; NP, not particular; INL, inner nuclear layer; RPE, retinal pigment epithelium. *Specific antibodies against retina or brain are marked in bold.
Treatment of Neoplasm Treatment of RetinopathyVisual Fields
Leakage
 in FA
Case No.,
Age at
Diagnosis,
Sex
Chief
 Complaint
Initial BCVA
ERG
Tumor
